- MeSH
- Amlodipine administration & dosage adverse effects therapeutic use MeSH
- Antihypertensive Agents administration & dosage adverse effects therapeutic use MeSH
- Arginine administration & dosage adverse effects therapeutic use MeSH
- Calcium Channel Blockers * administration & dosage adverse effects therapeutic use MeSH
- Drug Therapy methods trends utilization MeSH
- Hypertension * drug therapy prevention & control MeSH
- Clinical Trials as Topic methods utilization MeSH
- Drug Therapy, Combination methods trends utilization MeSH
- Humans MeSH
- Medication Therapy Management organization & administration trends utilization MeSH
- Meta-Analysis as Topic MeSH
- Perindopril * administration & dosage adverse effects therapeutic use MeSH
- Statistics as Topic MeSH
- Check Tag
- Humans MeSH
- MeSH
- Angiotensin II Type 1 Receptor Blockers administration & dosage metabolism therapeutic use MeSH
- Diabetes Mellitus * diagnosis drug therapy prevention & control MeSH
- Enalapril administration & dosage metabolism therapeutic use MeSH
- Clinical Trials as Topic methods standards utilization MeSH
- Controlled Clinical Trials as Topic methods utilization MeSH
- Drug Therapy, Combination * methods trends utilization MeSH
- Humans MeSH
- Neprilysin antagonists & inhibitors metabolism therapeutic use MeSH
- Early Termination of Clinical Trials MeSH
- Heart Failure * diagnosis classification therapy MeSH
- Statistics as Topic MeSH
- Valsartan administration & dosage metabolism therapeutic use MeSH
- Check Tag
- Humans MeSH
- MeSH
- Biomedical Research methods trends MeSH
- Diabetes Mellitus MeSH
- Drug Evaluation methods trends utilization MeSH
- Clinical Trials as Topic * methods organization & administration utilization MeSH
- Evidence-Based Practice methods trends MeSH
- Humans MeSH
- Proof of Concept Study MeSH
- Pragmatic Clinical Trials as Topic * classification methods utilization MeSH
- Randomized Controlled Trials as Topic * methods utilization MeSH
- Statistics as Topic MeSH
- Check Tag
- Humans MeSH
- MeSH
- Biomarkers MeSH
- Early Diagnosis MeSH
- Early Medical Intervention methods trends utilization MeSH
- Diagnostic Techniques, Neurological trends utilization MeSH
- Diagnostic Imaging methods trends utilization MeSH
- Phenotype MeSH
- Glatiramer Acetate administration & dosage adverse effects therapeutic use MeSH
- Interferons administration & dosage adverse effects therapeutic use MeSH
- Clinical Trials as Topic methods utilization MeSH
- Disease Attributes MeSH
- Humans MeSH
- Magnetic Resonance Imaging methods trends utilization MeSH
- Medication Therapy Management * standards trends utilization MeSH
- Antibodies, Monoclonal administration & dosage adverse effects therapeutic use MeSH
- Tomography, Optical Coherence methods trends utilization MeSH
- Disease Progression MeSH
- Multiple Sclerosis * diagnosis etiology therapy MeSH
- Practice Guidelines as Topic standards MeSH
- Statistics as Topic MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
- Keywords
- Cílový krevní tlak, Analýza výsledků studie SPRINT,
- MeSH
- Monitoring, Ambulatory methods trends utilization MeSH
- Antihypertensive Agents therapeutic use MeSH
- Circadian Rhythm physiology drug effects MeSH
- Cardiovascular Diseases etiology prevention & control MeSH
- Clinical Trials as Topic methods utilization MeSH
- Comorbidity MeSH
- Blood Pressure physiology drug effects MeSH
- Humans MeSH
- Blood Pressure Determination * methods standards utilization MeSH
- Meta-Analysis as Topic MeSH
- Prospective Studies MeSH
- Statistics as Topic MeSH
- Body Weight physiology drug effects MeSH
- Age Factors MeSH
- Check Tag
- Humans MeSH
- Keywords
- Kongres EASD 2016,
- MeSH
- Dementia diagnosis etiology metabolism MeSH
- Diabetes Mellitus * drug therapy MeSH
- Diabetic Nephropathies etiology drug therapy physiopathology MeSH
- Epigenomics methods trends MeSH
- Glucagon-Like Peptide 1 analogs & derivatives metabolism therapeutic use MeSH
- Drug Evaluation * MeSH
- Angiotensin-Converting Enzyme Inhibitors therapeutic use MeSH
- Cardiovascular System drug effects MeSH
- Clinical Trials as Topic methods utilization MeSH
- Diabetes Complications * etiology drug therapy MeSH
- Congresses as Topic MeSH
- Humans MeSH
- Drug-Related Side Effects and Adverse Reactions complications prevention & control MeSH
- Sodium-Glucose Transport Proteins administration & dosage adverse effects therapeutic use MeSH
- Check Tag
- Humans MeSH
- MeSH
- Diabetes Mellitus, Type 1 diagnosis prevention & control therapy MeSH
- Diabetes Mellitus, Type 2 diagnosis prevention & control therapy MeSH
- Diabetes Mellitus * metabolism prevention & control therapy MeSH
- Hyperglycemia complications prevention & control therapy MeSH
- Hypoglycemia complications prevention & control therapy MeSH
- Hypoglycemic Agents administration & dosage adverse effects therapeutic use MeSH
- Informed Consent * standards psychology legislation & jurisprudence MeSH
- Insulin administration & dosage adverse effects therapeutic use MeSH
- Clinical Trials as Topic methods utilization legislation & jurisprudence MeSH
- Diabetes Complications metabolism prevention & control therapy MeSH
- Humans MeSH
- Human Rights standards education legislation & jurisprudence MeSH
- Metabolic Diseases complications prevention & control psychology MeSH
- Patient Education as Topic * methods standards legislation & jurisprudence MeSH
- Physician-Patient Relations ethics MeSH
- Check Tag
- Humans MeSH
Randomizovaná, dvojitě zaslepená studie srovnala použití kovového (BMS) a bezpolymerového lékového stentu (DES) při léčbě nemocných s vysokým rizikem krvácení. Všichni nemocní byli léčeni duální protidestičkovu léčbou po dobu 1 měsíce a sledováni více než 1 rok. Biolimový stent snižuje u nemocných s vysokým rizikem krvácení pravděpodobnost další revaskularizace o 50 %, pravděpodobnost infarktu myokardu o 32 %.
In a randomized, double-blind trial, drug-coated stent was compared with bare metal stent in patients with a high risk of bleeding. All patients received 1 month of dual antiplatelet therapy and were followed more than one year. Treatment with drug-coated stent led to 50 % decrease in target vessel revascularization and to 32 % decrease of myocardial infarction.
- Keywords
- bezpolymerový lékový stent (DES), kovový stent (BMS), studie LEADERS FREE,
- MeSH
- Aspirin MeSH
- Platelet Aggregation Inhibitors MeSH
- Clinical Trials as Topic * methods utilization MeSH
- Hemorrhage complications prevention & control MeSH
- Humans MeSH
- Risk Factors MeSH
- Sirolimus analogs & derivatives adverse effects therapeutic use MeSH
- Statistics as Topic MeSH
- Drug-Eluting Stents * adverse effects trends utilization MeSH
- Stents * adverse effects trends utilization MeSH
- Outcome and Process Assessment, Health Care methods utilization MeSH
- Check Tag
- Humans MeSH
Chemoterapie se v léčbě karcinomu močového měchýře uplatňuje u všech klinických stadií. Její podání je indikováno dle doporučení Evropské urologické společnosti (EAU guidelines) jak u neinvazivních forem (A), tak v neoadjuvantním (1a) a adjuvantním (A) v případě klinických studií a pro nemocné s pozitivními uzlinami bez neoadjuvantní léčby (C) podání u invazivních nádorů. Jasné místo má v léčbě nemocných s metastatickým onemocněním (1b) jak pro první linii založenou na cisplatině tak pro vinflunin v druhé linii. Imunoterapie přináší nové možnosti léčby metastatického uroteliálního karcinomu močového měchýře.
Chemotherapy in treating bladder cancer is used in all clinical stages. Its administration is indicated according to the European Association of Urology guidelines in both non-invasive forms (A) and neoadjuvant (1a) and adjuvant (A) in the case of clinical trials and for patients with positive nodes without neoadjuvant therapy (C) administration in invasive tumours. It has a clear role in treating patients with metastatic disease (1b) both for the cisplatin-based first line and for vinflunine in the second line. Immunotherapy brings new treatment options for metastatic urothelial carcinoma of the urinary bladder.
- Keywords
- Vinflunin (druhá linie terapie), Pembrolizumab ( imunoterapie),
- MeSH
- Chemotherapy, Adjuvant methods utilization MeSH
- Administration, Intravesical MeSH
- Cisplatin administration & dosage adverse effects therapeutic use MeSH
- Drug Therapy * methods utilization MeSH
- Immunotherapy * methods utilization MeSH
- Clinical Trials as Topic methods utilization MeSH
- Humans MeSH
- Neoplasm Metastasis drug therapy therapy MeSH
- Urinary Bladder Neoplasms * diagnosis etiology therapy MeSH
- Neoadjuvant Therapy methods utilization MeSH
- Palliative Care methods utilization MeSH
- Antineoplastic Combined Chemotherapy Protocols MeSH
- Practice Guidelines as Topic MeSH
- Statistics as Topic MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
- Keywords
- katetrizační intervence vrozených a získaných srdečních vad, katetrizační uzávěry paravalvulárních leaků,
- MeSH
- Mitral Valve Annuloplasty methods trends utilization MeSH
- Echocardiography methods trends utilization MeSH
- Clinical Trials as Topic methods utilization MeSH
- Humans MeSH
- Meta-Analysis as Topic MeSH
- Minimally Invasive Surgical Procedures * methods trends utilization MeSH
- Mitral Valve abnormalities surgery physiopathology MeSH
- Mitral Valve Insufficiency diagnosis etiology surgery MeSH
- Heart Valve Diseases * diagnosis etiology surgery MeSH
- Pulmonary Valve abnormalities surgery physiopathology MeSH
- Heart Ventricles abnormalities surgery MeSH
- Statistics as Topic MeSH
- Pulmonary Valve Stenosis diagnosis etiology surgery MeSH
- Transcatheter Aortic Valve Replacement MeSH
- Tricuspid Valve Insufficiency diagnosis etiology surgery MeSH
- Check Tag
- Humans MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
